Introducing our new Managing Director, Tal Levy


We are very pleased to announce the planned transition of Managing Director duties from Giuseppe Carloni to Tal Levy, effective January 1st, 2022.

Tal is a passionate and trusted leader in the biopharmaceutical industry and has more than 15 years in biopharma manufacturing and supply chain operations. He brings with him a wealth of experience in areas that are key to the success and growth of FinVector Oy.

In taking over the MD role, Tal said: “I am excited to join FinVector Oy in the position of a Managing Director, supporting and leading the company and the great team in Kuopio (Finland) with our unique journey towards Adstiladrin commercialization. I want to thank my new team for their warm welcoming and support, looking forward to start collaborating with you. A special appreciation to our Board of Directors and the Chairman of the Board, for their trust and believe - I am honored and privileged to lead this front-line company with the mission of bringing a novel breakthrough treatment for our patients. Happy and successful 2022 to all.

It has been a privilege to lead this talented and dedicated team during the last 18 months and I am immensely proud of the progress made together towards delivering a gold-standard solution to an unmet medical need. I am confident Tal will continue and accelerate the improvement and take the Company to next level of performance.” Giuseppe said in a statement. Giuseppe Carloni will continue his collaboration with FinVector as the new member of Board of Directors.

Welcome to FinVector Tal!